Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1617 in Healthy Adult Non-Asian and Japanese Subjects Including Assessment of a Food Effect
- First Posted Date
- 2019-09-04
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 97
- Registration Number
- NCT04077879
- Locations
- 🇺🇸
California Clinical Trials Medical Group / Parexel, Glendale, California, United States
A Study to Assess ASP2713 in Healthy Subjects
- First Posted Date
- 2019-07-12
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Registration Number
- NCT04017208
A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 501
- Registration Number
- NCT04003142
- Locations
- 🇺🇸
Comprehensive Clinical Development, West Palm Beach, Florida, United States
🇺🇸Hwc Women's Research Center, Englewood, Ohio, United States
🇨🇦Site CA15002, Sherbrooke, Quebec, Canada
A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 527
- Registration Number
- NCT04003155
- Locations
- 🇺🇸
National Research Institute - Panorama, Los Angeles, California, United States
🇺🇸Emerson Clinical Research Institute, Washington, District of Columbia, United States
🇺🇸Advanced Clinical Research - Rancho Paseo, Banning, California, United States
A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 1831
- Registration Number
- NCT04003389
- Locations
- 🇺🇸
Neuro-Behavioral Clinical Research, Inc, North Canton, Ohio, United States
🇺🇸Aventiv Research, Inc., Columbus, Ohio, United States
🇺🇸Complete Healthcare For Women, Columbus, Ohio, United States
A Study to Assess Potential Interaction Between ASP8062 and Alcohol in Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04003402
- Locations
- 🇺🇸
Parexel International - EPCU Baltimore, Baltimore, Maryland, United States
A Study to Assess the Relative Bioavailability of Gilteritinib Following a Single Dose of Gilteritinib Mini-tablet Oral Suspension and Gilteritinib Mini-tablets Compared to a Single Dose of Gilteritinib Tablet in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT03964038
- Locations
- 🇺🇸
EPCU - Parexel, Baltimore, Maryland, United States
A Study to Assess the Relative Bioavailability of Roxadustat Following a Single Dose of Pediatric Azo Dye-free Tablet Formulation and Pediatric Azo Dye-free Mini-tablet Formulation Compared to a Single Dose of Azo Dye-containing Tablet Formulation in Healthy Adult Subjects
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT03960489
- Locations
- 🇩🇪
Site DE49001, Berlin, Germany
A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-05-17
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT03954067
- Locations
- 🇺🇸
The University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 393
- Registration Number
- NCT03816163
- Locations
- 🇺🇸
Lynn Cancer Institute, Boca Raton, Florida, United States
🇹🇷Site TR90002, Istanbul, Turkey
🇺🇸St. Joseph Heritage Medical Group, Fullerton, California, United States